Drug profile · INN
minoxidil
LONITEN
minoxidil (LONITEN) is a sulfonylurea receptor 2, kir6.2 opener. Associated with Pfizer Australia Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Drug details — minoxidil
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 4
- Programs
- 5
- Data quality
- 0.89
Quick answer
minoxidil (LONITEN) is a sulfonylurea receptor 2, kir6.2 opener. Associated with Pfizer Australia Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Sulfonylurea receptor 2, Kir6.2 opener
Primary target: Sulfonylurea receptor 2, Kir6.2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2026057588
POLYTHÉRAPIE À BASE DE CLASCOTÉRONE ET DE MINOXIDIL POUR LE TRAITEMENT DE LA PERTE DES CHEVEUX
granted -
AR 132316
TRATAMIENTO COMBINADO CON CLASCOTERONA Y MINOXIDIL
granted -
US 12268688
Compositions and methods of use for modified release minoxidil
granted -
US 11617796
Conjugate of minoxidil and peptide
granted
Frequently asked questions
What is minoxidil?
minoxidil (LONITEN) is a sulfonylurea receptor 2, kir6.2 opener. Associated with Pfizer Australia Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for minoxidil?
LONITEN is a marketed brand name for minoxidil. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of minoxidil?
minoxidil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.